Related Experiment Video
Updated: Aug 11, 2025

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis
Published on: September 26, 2018
Improving the Prediction of Death from Cardiovascular Causes with Multiple Risk Markers
Xin Wang1, Kelly M Bakulski1, Samuel Fansler2
1Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, MI, United States.
Insights
Adding clinical blood biomarkers and blood counts significantly improves cardiovascular disease (CVD) mortality prediction beyond traditional risk factors. These factors offer a valuable tool for public health screening and CVD prevention strategies.
Area of Science:
- Cardiovascular Medicine
- Biomarkers
- Public Health
Background:
- Traditional risk factors predict some cardiovascular disease (CVD) events, but the utility of additional routinely measured factors remains unclear.
- This study aimed to assess if a comprehensive list of risk factors, including clinical blood measures and counts, enhances CVD mortality prediction beyond established metrics.
Approach:
- Utilized National Health and Nutrition Examination Survey (NHANES) data (2001-2016) from 21,982 adults (≥40 years), linked to mortality data through 2019.
- Compared prediction models using traditional risk factors versus models incorporating additional clinical blood biomarkers, complete blood counts, anthropometric measures, dietary factors, and lifestyle questions.
- Employed Cox proportional hazards regression, elastic-net penalized Cox regression, and random survival forest, evaluating model performance with C-index and net reclassification improvement.
Key Points:
- Incorporating clinical blood biomarkers and complete blood counts significantly improved CVD mortality prediction (C-index increased from 0.850 to 0.867 and 0.861, respectively).
- The addition of all 113 predictors collectively enhanced CVD mortality classification (C-index=0.871).
- Net reclassification improvement was notable, with clinical blood biomarkers adding 13.2% and all predictors adding 12.2%.
Conclusions:
- Clinical blood biomarkers and blood counts substantially enhance the prediction of cardiovascular disease mortality.
- These routinely measurable factors show potential as crucial clinical and public health screening tools for preventing CVD deaths.
Background:
Traditional risk factors including demographics, blood pressure, cholesterol, and diabetes status are successfully able to predict a proportion of cardiovascular disease (CVD) events. Whether including additional routinely measured factors improves CVD prediction is unclear. To determine whether a comprehensive risk factor list, including clinical blood measures, blood counts, anthropometric measures, and lifestyle factors, improves prediction of CVD deaths beyond traditional factors.
Methods:
The analysis comprised of 21,982 participants aged 40 years and older (mean age=59.4 years at baseline) from the National Health and Nutrition Examination Survey (NHANES) from 2001 to 2016 survey cycles. Data were linked with the National Death Index mortality data through 2019 and split into 80:20 training and testing sets. Relative to the traditional risk factors (age, sex, race/ethnicity, smoking status, systolic blood pressure, total and high-density lipoprotein cholesterol, antihypertensive medications, and diabetes), we compared models with an additional 22 clinical blood biomarkers, 20 complete blood counts, 7 anthropometric measures, 51 dietary factors, 13 cardiovascular health-related questions, and all 113 predictors together. To build prediction models for CVD mortality, we performed Cox proportional hazards regression, elastic-net (ENET) penalized Cox regression, and random survival forest, and compared classification using C-index and net reclassification improvement.
Results:
During follow-up (median, 9.3 years), 3,075 participants died; 30.9% (1,372/3,075) deaths were from cardiovascular causes. In Cox proportional hazards models with traditional risk factors (C-index=0.850), CVD mortality classification improved with incorporation of clinical blood biomarkers (C-index=0.867), blood counts (C-index=0.861), and all predictors (C-index=0.871). Net CVD mortality reclassification improved 13.2% by adding clinical blood biomarkers and 12.2% by adding all predictors. Results for ENET-penalized Cox regression and random survival forest were similar. No improvement was observed in separate models for anthropometric measures, dietary nutrient intake, or cardiovascular health-related questions.
Conclusions:
The addition of clinical blood biomarkers and blood counts substantially improves CVD mortality prediction, beyond traditional risk factors. These biomarkers may serve as an important clinical and public health screening tool for the prevention of CVD deaths.
Related Concept Videos
Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Coronary Artery Disease I: Introduction
Coronary Artery Disease IV: Preventive Measures
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
Atherosclerosis III: Management

